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Introduction
Depression is a major disorder of mood, affecting 
approximately 340 million people worldwide. It is the third 
leading cause of burden from disease, and accounts for 
4.5% of all human suffering.1 The most recent estimated 
lifetime prevalence of major depression in South Africa is 
9.7%, with a 12-month prevalence of 4.9%, which tends 
to be higher in women, than in men, as well as in those 
with a low level of education.2 This chronic, debilitating, 
and sometimes fatal illness, is associated with considerable 
costs to patients, their families, and to society, and is often 
difficult to treat. 
Traditional theories about the pathogenesis of depression 
include the monoamine hypothesis, which implicates a 
lack of noradrenaline and serotonin (5HT), and the receptor 
hypothesis, which proposes the upregulation of certain 
noradrenergic and serotonergic receptors, and their 
subsequent downregulation in response to treatment.3,4 
The two theories are not mutually exclusive, and have 
arisen from attempts to elucidate the mechanisms of action 
of serendipitously discovered, as well as more innovative 
antidepressants. 
Most antidepressant agents act by increasing the availability 
of the monoamines at neuronal synapses, particularly in 
the locus coeruleus (noradrenaline) and raphe nucleus 
(serotonin). The pioneering tricyclic antidepressants 
(TCAs) and monoamine oxidase inhibitors (MAOIs) inhibit 
their reuptake and metabolism, respectively. The more 
recent antidepressants, including selective serotonin 
reuptake inhibitors (SSRIs), serotonin and noradrenaline 
reuptake inhibitors (SNRIs), noradrenergic and specific 
serotonergic antidepressants (NaSSAs) and noradrenaline 
reuptake inhibitors (NARIs) also act chiefly through 
these monoaminergic mechanisms. The noradrenaline 
and dopamine reuptake inhibitor (NDRI), bupropion, is 
slightly unusual because it also increases dopamine 
neurotransmission, chiefly in the nucleus accumbens and 
prefrontal cortex.
An alternative or perhaps additional approach to the 
pathogenesis of depression is rooted in circadian biology. 
This hypothesis focuses on the circadian regulation of 
biological rhythms, and its relationship with depression and 
the monoamine systems.
Normal circadian rhythms and the role of 
melatonin
The 24-hour rhythms of life, including the timing of 
sleep induction, wakefulness, hormone secretion, 
thermoregulation, glucose homeostasis and fat meta-
bolism, are governed by external environmental time signals 
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P 1A2 (CYP1A2) enzyme inhibitors, which may increase agomelatine’s plasma levels significantly. Agomelatine represents 
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(zeitgebers), particularly fluctuations in light intensity (photic 
zeitgebers). These bodily rhythms are also controlled by an 
internal circadian timekeeping system, that comprises a 
host of peripheral, tissue-specific molecular clocks that are 
able to operate independently of external time cues, and a 
central (anterior hypothalamic) master clock-like pacemaker, 
the suprachiasmatic nucleus (SCN) that is synchronised to 
geophysical or solar time, chiefly via photic input.5 
Melatonin (N-acetyl-5-methoxytryptamine), produced 
from the neurotransmitter serotonin, acts as a non-photic 
message, and interacts with photic signals in the control of 
circadian and diurnal cycles. It is a critical synchroniser of 
biological rhythms, including the sleep-wake cycles, and its 
secretion from the pineal gland is closely linked to light-dark 
and seasonal cycles. During the day, non-image-forming 
light (photic zeitgeber) activates the retino-hypothalamic 
tract that connects the eye to the SCN. The SCN inhibits 
the pineal gland indirectly, via inhibition of noradrenergic 
input from the superior cervical ganglion. In this way, light 
suppresses the production and release of melatonin from 
the pineal gland. Dark has the opposite effect and causes 
a surge of melatonin, which usually peaks in the middle of 
the night and gradually falls during the second half. In turn, 
once stimulated by dark, melatonin binds to an important 
population of melatonin receptors, including M1 and M2, in 
the SCN, where it is able to reset circadian rhythms in phase 
with the prevailing environmental conditions. Melatonin is 
also able to acutely inhibit SCN neuronal firing, which 
may increase the SCN’s sensitivity to other phase-shifting 
stimuli.5,6
Two other modulators of SCN function are the daily 
behaviours themselves, and perhaps more pertinently, 
serotonin (5HT), the synthesis of which is highly circadian. 
Serotonergic projections from the raphe nucleus are able 
to modify SCN responses, and this is thought to be mainly 
via serotonin binding to the 5-HT2C receptor subtype. In 
rats, it has been suggested that 5HT2c receptor agonists 
may actually mimic light, and induce a phase shift.7 
Interestingly, activity at 5HT2c receptors appears to be 
increased in depression, and decreases in response to 
certain antidepressant therapies, including clomipramine, 
mirtazapine, sleep deprivation, and electroconvulsive 
therapy. 5HT2c antagonists appear to favourably influence 
mood, circadian resynchronisation and sleep quality, while 
preserving sexual function.6
Circadian rhythms in depression
Circadian function is often disrupted in depression. The 
internal circadian timekeeping system responds poorly 
to environmental cues, resulting in phase shifts. Diurnal 
variations occur earlier (phase advance) or later (phase 
delay) than in healthy individuals. Patients with depression 
often show larger daytime mood variation, disturbances 
in hypothalamic-pituitary-adrenal (HPA) axis function, 
more severe cognitive difficulties, and sleep-wake cycle 
disturbances, which may manifest as delayed onset of 
sleep, difficulty in maintaining sleep, and early morning 
awakening. The degree of circadian misalignment correlates 
with the severity of depression, although the causal 
relationship remains unclear.8 Thus, circadian abnormalities 
may partially be a consequence of alterations in behaviour 
and sleep patterns that accompany depression. They may 
also be triggered by an intrinsic disorganisation of the SCN. 
Importantly, depression is associated with an altered diurnal 
rhythm of melatonin output, including a suboptimal night-
time surge. It appears that increasing levels of endogenous 
melatonin are associated with effective conventional 
antidepressant therapy. It is noteworthy that commercially 
available melatonin, which binds to melatonergic 
receptors, may improve sleep function, but appears to 
be ineffective in alleviating depression, indicating that the 
circadian stabilising effect of 5HT2c antagonism remains 
therapeutically important.9 Overall, the circadian hypothesis 
supports the notion that resetting circadian function is a 
relevant strategy to treat depression.6 
Agomelatine
Agomelatine, the first regulatory approved melatonergic 
antidepressant, is a naphthalene derivative of melatonin. 
Therefore, it is more lipophilic and shows improved brain 
penetration compared to the indole of melatonin. It is a 
potent full agonist of the human melatonergic receptors, 
melatonin 1 (MT1) and melatonin 2 (MT2). Like melatonin, 
agomelatine acutely and dose-dependently inhibits the firing 
rate of SCN neurons (MT1) and directly resynchronises and 
normalises disturbances of circadian rhythm (MT2).
10 The 
greatest effectiveness appears to coincide with the onset of 
the elevation in night-time melatonin secretion, presumably 
the period of highest melatonin receptor density. A transient 
and short activation of melatonergic receptors at this 
critical time appears to be sufficient for its enduring effects, 
illustrated by a reduction in body temperature, increased 
total sleep time, fewer awakenings after sleep onset, and by 
the advance in time at which the minimum heart rate occurs 
during the 24-hour cycle.6,11
Agomelatine also binds to 5HT2c receptors, albeit with 
substantially lower affinity than to the melatonin receptors. 
Nonetheless, it acts as an antagonist of these receptors, 
which contributes to its resynchronisation of circadian 
rhythms, enhancement of dopaminergic and adrenergic 
input to the frontal cortex, induction of hippocampal 
neurogenesis, and ultimately, to its antidepressant effect.6 
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5HT2c antagonism is also beneficial for alleviating other 
symptoms associated with 5HT2c overstimulation, including 
anxiety, insomnia and sexual dysfunction. Thus, the additive 
or perhaps even the synergistic action of agomelatine at 
both the melatonin and 5HT2c receptors, appears to be 
necessary for its efficacy in treating depression.6
Agomelatine is licensed for the treatment of major depressive 
episodes in adults. It received European Union marketing 
authorisation in February 2009, and is now licensed for use 
in South Africa.12
Efficacy of agomelatine in treating major 
depression
Several published clinical trials in almost 6 000 depressed 
patients, have examined agomelatine’s efficacy compared 
to placebo, SSRI and SNRI treatment, both in the acute and 
long-term or maintenance setting. It is worth noting that five 
unpublished trials did not find agomelatine to be superior 
to placebo, even though in two of these trials, the active 
comparitors were more effective than placebo. One clinical 
trial, showing lack of efficacy in relapse prevention, was 
also not published.13 This highlights the issue of reporting 
and publication bias, and the role that it plays in evidence-
based decision making. The results below are based on the 
published literature.
Acute efficacy vs. placebo
In three 6-8 week, double-blind randomised placebo 
controlled studies, agomelatine used at a dose of 25-
50 mg at bedtime, demonstrated significantly superior 
efficacy compared to placebo in both moderate and severe 
depression, using the Hamilton Depression Rating Scale 
(HAMD-17) as the primary outcome measure.14-16 A clinically 
relevant 2.86 point mean difference was shown.17 The onset 
of antidepressant action appeared to be more rapid (week 
two) than the active comparator, paroxetine, in one of these 
studies.14 More recent placebo-controlled trials showed 
significant efficacy, including positive effects on sleep, with 
good tolerability in moderate to severe depression.18,19
Acute efficacy vs. other antidepressants 
Agomelatine (25-50 mg) showed non-inferiority compared 
to the SSRI, sertraline (50-100 mg) with a greater 
proportion of responders at week 2, as well as to the SNRI, 
venlafaxine (75-150 mg) in clinical trials of 6-12 weeks’ 
duration.20-23 Compared to venlafaxine XR, fewer patients 
in the agomelatine group discontinued treatment because 
of adverse events (agomelatine 2.2%, vs. venlafaxine XR 
8.6%), although both treatments resulted in equivalently 
high rates of remission (agomelatine 73%, venlafaxine XR 
66.9%).23 Agomelatine was effective across the range of 
severities of depression, including in patients with severe 
depression. It also accounted for early improvements in 
daily functioning and sleep, compared to sertraline and 
venlafaxine. 
Other comparators have included paroxetine and 
fluoxetine.14,24,25 Eight weeks of agomelatine showed 
superior antidepressant efficacy, compared to fluoxetine in 
treating patients with a severe episode of major depressive 
disorder. However, there were no differences in response 
rates, remission rates and dropouts, due to treatment 
(emergent adverse effects between the two drugs).25 
Long-term efficacy
In a 24-week relapse prevention study, patients who 
continued taking agomelatine showed a twofold lower 
relapse rate (21.7% vs. 46.6%) compared to those who 
were switched to placebo, and they maintained this 
advantage for up to 10 months.26 In another 24-week study, 
agomelatine also demonstrated non-inferiority compared to 
escitalopram.27
Sleep disturbances
Many years ago, acute placebo-controlled studies in 
healthy volunteers showed that agomelatine increased 
rapid eye movement (REM) sleep propensity and advanced 
sleep termination, and resulted in earlier regulation of the 
endogenous circadian nocturnal decline in core body 
temperature with circadian phase advance.28,29 These 
findings were corroborated a decade later in a study of 
depressed patients, where although the six-week efficacy 
of agomelatine was similar to venlafaxine, sleep quality 
measured with the Leeds Sleep Evaluation Questionnaire 
was subjectively better among patients treated with 
agomelatine.22 In a small, single-blinded study, agomelatine 
improved slow-wave sleep without causing daytime 
drowsiness, while an open-label polysomnography and 
qualitative electroencephalogram study in patients with 
depression, demonstrated improvements in sleep efficiency 
and fewer intra-sleep awakenings.30,31 More recently, this 
was confirmed in a large multicentre randomised double-
blind study comparing the effects of agomelatine and 
escitalopram for a period of 24 weeks.27 Agomelatine 
improved sleep latency from the second week, did not 
affect REM sleep or sleep cycles, and also did not lead to 
daytime drowsiness.
Symptoms of anxiety in depressed patients
Anxiety symptoms in depressed patients are common, and 
are associated with a worse prognosis, increased disability, 
and higher use of medication. In addition, a common early 
side-effect of antidepressants that increase serotonin, is 
treatment emergent anxiety, thought to be partly due to the 
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overstimulation of post-synaptic 5HT2 receptors. Six large 
multicentre studies, each with a duration of six to eight 
weeks, involving approximately 2 000 patients with major 
depressive disorder, assessed the efficacy of agomelatine 
in treating the symptoms of anxiety in depressed patients. 
Among these, more than 900 patients were classified as 
severely anxious, defined by a score of at least five points 
on the anxiety subscale of the Hamilton Depression Rating 
Scale (HAM-D).32
Three of the six studies compared agomelatine to the 
SSRIs, sertraline and fluoxetine, and the SNRI, venlafaxine. 
Agomelatine was shown to be more effective in reducing 
symptoms of anxiety than its comparators. It led to a 
significant difference on the Hamilton Anxiety Rating 
Scale (HAM-A) of 1.39 points. The beneficial effects of 
agomelatine, compared to the comparator drugs, was more 
pronounced in the highly anxious depressed patients, with 
a difference of 1.72 recorded on the HAM-A.32
In the other three studies where agomelatine was compared 
to placebo, agomelatine was found to significantly reduce 
anxiety scores on the HAM-D anxiety subscore, as early 
as the second week. This rapid improvement resulted in 
a significant efficacy over the course of the study, which, 
once again, was even greater in the more anxious subset 
of patients.32
Other disorders
In a robust 12-week, double-blind randomised controlled 
trial conducted in South Africa and Finland, agomelatine at 
normal therapeutic dose (25-50 mg) showed significantly 
superior efficacy compared to placebo in the treatment of 
generalised anxiety disorder.33 Agomelatine’s efficacy has 
also been explored in obsessive compulsive disorder in 
two recent studies.34,35 Agomelatine has shown promise in 
seasonal affective disorder in a 14-week open-label study, 
where patients showed high response and remission rates.36 
Its efficacy in depression in bipolar I patients, in combination 
with either lithium or valproate, has also been assessed in 
an open-label study ranging from 6- 46 weeks.37 In addition, 
it has been suggested that agomelatine may show efficacy 
in the long-term maintenance treatment of alcoholism, 
to prevent alcohol-related brain damage.38 Other areas 
of research include its use as an adjunct in autism and 
benzodiazepine withdrawal.39,40
Pharmacokinetics and drug interactions12 
Agomelatine, formulated as a 25-mg film-coated tablet, is 
taken orally at bedtime. It is rapidly absorbed with a peak 
plasma concentration reached within one to two hours of a 
single dose. Food does not affect its absorption. However, 
there is substantial inter-individual variation in plasma levels, 
which is increased with high fat-containing food. 
In the therapeutic dose range (25-50 mg), agomelatine’s 
systemic exposure increases proportionately with dose. 
However, at significantly higher doses (> 200 mg and 
above), saturation of first pass metabolism occurs, and 
plasma levels may increase disproportionately.
Agomelatine has a short half-life of one to two hours, which 
is sufficient for binding to melatonin receptors at the critical 
nocturnal time point. Biotransformation is predominantly 
achieved by hepatic cytochrome P1A2 (CYP1A2) isoenzyme 
hydroxylation (90%), followed by the smaller demethylation 
contributions of CYP2C9 and CYP2C19 (10%). The major 
metabolites are inactive, are rapidly conjugated and are 
eliminated in the urine thereafter. 
Absolute bioavailability is low (< 5%) and this is increased 
in women, and by co-administered oral contraceptives 
and potent hepatic CYP1A2 isoenzyme inhibiting agents 
such as the SSRI, fluvoxamine, and the fluoroquinolone, 
ciprofloxacin. Therefore, agomelatine is contraindicated 
if the latter two drugs are prescribed. In theory, moderate 
CYP1A2 enzyme inhibitors (paroxetine, oestrogens, 
propranolol, grepafloxacin and enoxacin) may result in 
increased levels of agomelatine, and caution should be 
exercised when prescribing these agents. In practice, it 
appears that interactions are only likely to occur with drugs 
that inhibit both enzyme pathways.
Enzyme inducers (omeprazole and smoking) diminish 
agomelatine’s bioavailability by up to three- to fourfold, 
and ultimately, the higher 50 mg dose may be necessary to 
achieve a therapeutic effect. Hypothetically, if these agents 
are discontinued, the levels of agomelatine may increase 
and possibly lead to tolerability issues.
Agomelatine itself has no inducing or inhibiting effects 
on the metabolising CYP450 enzymes mentioned above. 
The potential for agomelatine to affect exposure to other 
medicinal products metabolised by these enzymes is 
negligible. There has been no evidence of drug interactions 
with agomelatine when it is given concurrently with 
benzodiazepines, lithium, paroxetine, fluconazole or 
theophylline.
Agomelatine is distributed moderately, 95% of drug 
protein-bound. In practice, this is not sufficient to cause 
displacement of highly protein-bound drugs, such as warfarin 
and aspirin, nor should these drugs alter the unbound free 
concentrations of agomelatine. Of note, though, is that the 
free fraction is doubled in patients with hepatic impairment, 
presumably because of decreased albumin production, 
while bioavailability increases 70-140-fold.11 
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Tolerability of agomelatine12
Agomelatine has a relatively favourable side-effect profile. 
It is not associated with weight gain, heart rate or blood 
pressure changes. 
Theoretically, agomelatine is unlikely to cause the sexual 
dysfunction that is frequently associated with antidepressant 
use, because it blocks 5HT2c receptors. This was borne 
out in an eight-week, placebo-controlled study in healthy 
volunteers, that revealed that sexual dysfunction was 
significantly lower in those taking agomelatine, compared to 
those taking paroxetine.41 In a 12-week study in depressed 
patients, agomelatine showed a superior sexual side-effect 
profile compared to venlafaxine.23
Transient and mild nausea and dizziness are the most 
common adverse reactions, and these usually occur in the 
first two weeks and generally do not lead to cessation of 
treatment. In most studies, the incidence of these effects 
did not exceed those of placebo-treated patients.
Other common adverse effects include headaches, 
somnolence, insomnia, fatigue, migraines, emergent anxiety, 
gastrointestinal symptoms, hyperhidrosis, back pain, and 
raised liver transaminases, alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) (1.1% on agomelatine 
vs. 0.7% on placebo). 
Liver function
As noted, temporary increases in serum liver transaminases 
may occur in patients taking agomelatine, particularly the 
50 mg dose. For this reason, liver function tests should be 
performed in all patients prior to the initiation of treatment, 
and then after the acute phase (at six weeks), at 12 and at 24 
weeks, and thereafter, if clinically indicated. If transaminase 
values increase, liver function tests should be repeated 
within 48 hours, and closely monitored. Treatment should 
be discontinued if the levels of transaminases exceed three 
times the upper limit of normal.
Cautions and contraindications12
Agomelatine is contraindicated in patients taking 
ciprofloxacin or fluvoxamine, as these agents increase the 
plasma levels of agomelatine substantially.
It should be emphasised that agomelatine is contraindicated 
in hepatic disease, such as cirrhosis, or in any active liver 
disease. It may be prescribed cautiously though, to patients 
with risk factors for hepatic injury, including obesity (fatty 
liver disease), substantial alcohol intake, or to those on 
concomitant therapeutic agents that are associated with 
hepatotoxicity.
The plasma levels of agomelatine may increase by 25% in 
patients suffering renal impairment (creatinine clearance 
< 30 ml/minute). Therefore, caution should be exercised in 
this group of patients, particularly as limited clinical data is 
available.
Caution should also be exercised in elderly patients, with or 
without dementia, and in patients with a history of bipolar 
affective disorder, mania or hypomania, and agomelatine 
should be discontinued if these symptoms arise during 
treatment.
The effect of agomelatine on the foetus or breastfed babies 
has not been determined. Therefore, it should be used with 
extreme caution in pregnant and lactating women. Although 
melatonin is known to improve pregnancy rates, animal 
reproduction studies with agomelatine have not investigated 
this pro-fertility effect. What has been demonstrated in 
animals is that agomelatine has no detrimental effects on 
fertility. Its effects on human fertility are unknown.
Because of dizziness and somnolence, driving and operating 
machinery may be impaired in patients taking agomelatine.
Close supervision of patients, particularly those who are 
at increased risk of suicide, should accompany treatment, 
particularly in the early stages when the risk increases, and 
following dose adjustments. There is limited experience 
with agomelatine overdose, although doses up to 
2 450 mg have been taken without cardiovascular or 
biological abnormalities, and spontaneous recovery has 
occurred. Excessively high doses have resulted in epigastric 
pain, somnolence, fatigue, agitation, anxiety, tension, 
dizziness, cyanosis and malaise.
Clinical pearls
Starting treatment
Once liver function tests have been performed, agomelatine 
should be started at the therapeutic dose of 25 mg, taken 
at bedtime. If there is no improvement in symptoms after 
two weeks, the dose may be increased to 50 mg.12 Several 
additional factors may influence the dose, including the 
severity of the depression, its effect on the quality of life, 
the degree and rate of improvement seen with the existing 
dose, and any treatment-associated adverse effects. For 
instance, patients with depression of moderate severity who 
show an initial partial response to treatment, may not require 
a dose increase, given that the full antidepressant effect is 
usually only achieved after four to six weeks, whereas a 
partial response in a patient with severe illness and suicidal 
thoughts should probably warrant a dose adjustment.11 
Ideally, treatment should continue for six months after the 
resolution of symptoms.
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Stopping treatment
Usually antidepressants are tapered slowly, rather than 
discontinued abruptly, in order to minimise the potential 
for withdrawal symptoms.42 This is particularly true of 
agents with short half-lives. One clinical trial assessed 
discontinuation symptoms in patients following abrupt 
cessation of either agomelatine or paroxetine, using the 
traditional Discontinuation Emergent Symptom Scale (DESS) 
after 12 weeks of successful antidepressant treatment. As 
predicted, a significant increase in the DESS score was seen 
in the paroxetine group who switched to placebo vs. those 
who continued on paroxetine. No significant increase in the 
score was noted for patients on agomelatine who switched 
to placebo vs. those who continued on agomelatine.24 These 
initial findings were subsequently supported by a relapse 
prevention study, where after 8-12 weeks of agomelatine 
treatment, patients were randomised to either a placebo 
group, or continued with the agomelatine treatment. 
Patients who were switched to placebo showed no initial 
increase in symptoms, which reinforces the notion that 
the drug may be withdrawn abruptly.26 Nonetheless, until 
wider experience with the drug is obtained, patients should 
be advised to consult their doctor if they develop new or 
worsening symptoms in the week following discontinuation 
of the agomelatine. 
Switching to and from agomelatine
There are various ways of switching from one antidepressant 
to another. Usually, these are dictated by the pharmacology 
of the individual drugs and the clinical need. Strategies 
include switching abruptly from one antidepressant to 
another; gradually tapering down and stopping the first 
antidepressant (to avoid discontinuation reactions), before 
introducing the second drug, tapering down the first agent 
and introducing the second agent concurrently (either at 
a reduced or full dose) or incorporating a washout period 
between the two drugs. In order to avoid discontinuation 
effects, generally it is not necessary to taper the first 
drug if the second drug shares similar pharmacodynamic 
properties, for instance switching between the serotonergic 
SSRIs and SNRIs. The danger in this scenario is the 
emergence of serotonin toxicity, particularly with SSRIs, 
TCAs (clomipramine), SNRIs (venlafaxine and duloxetine), 
MAOIs, and trazodone. A drug washout period is mandatory 
when switching from an MAOI to any other agent for this 
reason. In addition, some SSRIs, such as fluoxetine and 
paroxetine, are potent inhibitors of CYP2D6, and concurrent 
administration of these agents with a TCA during the 
crossover period may result in a dangerous 200-400% 
increase in TCA plasma levels.11
Agomelatine does not increase serotonin levels. Therefore, 
the risk of serotonin syndrome should not increase if there 
is concurrent administration of an antidepressant with 
serotonergic effects during the crossover period. However, 
discontinuation reactions may be expected if stopping 
serotonergic agents. Therefore, they should probably be 
tapered down over a period of four weeks at the time of, 
or after introducing, agomelatine. The exception to this is 
fluoxetine, where discontinuation reactions are rare because 
of the extremely long half-life of its active metabolite. No 
tapering is required. Of note is that a quick switch from 
fluvoxamine to agomelatine is potentially dangerous, 
because of the significant increase in agomelatine’s plasma 
levels when the agents are prescribed concurrently. A gradual 
withdrawal of fluvoxamine, as well as a washout period of 
three days, is advised before instituting agomelatine.11
Switching from agomelatine to any other antidepressant 
should not elicit any problems because of its low potential 
for discontinuation reactions, accumulation (it has a very 
short half-life), pharmacodynamic and pharmacokinetic 
drug-drug interactions.11
Conclusion
Agomelatine is thought to act primarily by resynchronising 
the circadian clock, and therefore the abnormal circadian 
rhythms that are found in depression. However, in common 
with many other antidepressants, it also stimulates the 
release of the brain-derived neurotrophic factor, which 
increases neurogenesis in the brain, normalises cortisol 
production, and HPA axis function. It has demonstrated 
good efficacy and tolerability in published trials, yet there is 
a degree of controversy surrounding previously unpublished 
data. Monitoring of liver function may be cumbersome, and 
precludes its use in patients who are not willing to undertake 
this commitment. 
Good candidates for agomelatine therapy are those 
who have pronounced sleep disturbances and anxiety 
symptoms accompanying their depression, as well as those 
who experience sexual dysfunction, either as a result of the 
depression itself, or induced by SSRI or SNRI treatment. 
Agomelatine is a welcome addition to the antidepressant 
market and wider clinical usage will ultimately determine 
whether it lives up to its promise in the treatment of 
moderate and severe depression.
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